#USA #securities lawsuit #DJS Law Group #Eastchester, NY #ADMA Biologics

Class Action Lawsuit against ADMA Biologics, Inc.

In a notable development for investors, ADMA Biologics, Inc. (NASDAQ: ADMA) has become the target of a class action lawsuit. This legal action has been brought to light by the DJS Law Group, which is encouraging shareholders who experienced financial loss during the specified class period to come forward. This article delves into the details of the lawsuit, including the allegations against the company, and what affected investors should know.

Background on ADMA Biologics

ADMA Biologics, Inc. is a publicly traded company that specializes in the development of immune globulin products for the treatment of various infections. With its shares traded on NASDAQ under the ticker ADMA, the company has garnered interest from investors. However, allegations of misleading practices have now raised significant concerns.

The Allegations

According to the complaint, ADMA Biologics is accused of violating key provisions of the Securities Exchange Act of 1934, specifically Sections 10(b) and 20(a), along with Rule 10b-5 established by the U.S. Securities and Exchange Commission (SEC). The lawsuit claims that during the class period, which stretches from August 9, 2024, to March 25, 2026, ADMA failed to disclose critical information regarding a related party transaction. Furthermore, it is alleged that the firm engaged in practices that artificially inflated sales figures to present a misleading picture to the market.

Misleading Statements

The heart of the allegations is centered on the company's purportedly false and misleading statements made to investors throughout the class period. The claim points out that ADMA's public communications did not accurately reflect the company’s actual sales activity and financial standing, leading to investor losses when the true situation was eventually revealed.

What This Means for Investors

For shareholders who acquired ADMA shares during the specified class period and experienced a loss, there are essential steps to consider. The DJS Law Group is urging affected investors to contact them to discuss the possibility of being appointed as a lead plaintiff in the upcoming lawsuit. Importantly, becoming a lead plaintiff is not a requirement to join the case and pursue recovery of losses incurred.

What's Next?

The deadline for investors to join this class action lawsuit is set for August 10, 2026. This timeline is crucial as it defines the window for impacted shareholders to take action. Whether through direct contact with the DJS Law Group or other legal avenues, it is imperative for shareholders to act promptly.

The Role of DJS Law Group

The DJS Law Group focuses primarily on securities fraud cases, emphasizing investor rights and advocating for fair treatment in the financial markets. With a strong track record in securities class actions and corporate litigation, they offer specialized guidance for individuals navigating the complexities of such lawsuits.

If you believe you are a shareholder who has suffered due to ADMA’s alleged securities law infringements, do not hesitate to reach out to the DJS Law Group. Their expertise may prove invaluable as the case unfolds. With the potential for recovery of losses on the horizon, this situation remains a significant development in the realm of investor rights and corporate accountability.

Conclusion

In summary, the class action lawsuit against ADMA Biologics, Inc. highlights critical issues surrounding corporate transparency and investor protection. As developments unfold, investors are advised to stay informed and seek professional legal counsel to navigate their rights effectively. By coming together, affected shareholders may have the opportunity to recover their losses and hold the company accountable for its alleged actions.

For further information or to discuss your rights as an investor, please contact the DJS Law Group. Take action today to protect your investments.